Cytarabine; Daunorubicin Patent Expiration
Cytarabine; Daunorubicin is used for treating newly-diagnosed therapy-related acute myeloid leukemia (T-AML) or AML with myelodysplasia-related changes (AML-MRC) in children and adults. It was first introduced by Celator Pharmaceuticals Inc
Cytarabine; Daunorubicin Patents
Given below is the list of patents protecting Cytarabine; Daunorubicin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vyxeos | US10028912 | Method of lyophilizing liposomes | Oct 15, 2032 | Celator Pharms |
| Vyxeos | US10166184 | Method of lyophilizing liposomes | Oct 15, 2032 | Celator Pharms |
| Vyxeos | US10835492 | Method of lyophilizing liposomes | Oct 15, 2032 | Celator Pharms |
| Vyxeos | US8092828 | Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders | Apr 01, 2029 | Celator Pharms |
| Vyxeos | US8022279 | Liposomal formulations of anthracycline agents and cytidine analogs | Sep 14, 2027 | Celator Pharms |
| Vyxeos | US7850990 | Compositions for delivery of drug combinations | Jan 23, 2027 | Celator Pharms |
| Vyxeos | US9271931 | Compositions for delivery of drug combinations | Jan 23, 2027 | Celator Pharms |
| Vyxeos | US8518437 | Lipid carrier compositions with enhanced blood stability | Jun 07, 2026 | Celator Pharms |
| Vyxeos | US8431806 | Liposomal formulations of anthracycline agents and cytidine analogs |
Apr 22, 2025
(Expired) | Celator Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Cytarabine; Daunorubicin's patents.
Latest Legal Activities on Cytarabine; Daunorubicin's Patents
Given below is the list recent legal activities going on the following patents of Cytarabine; Daunorubicin.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 01 May, 2024 | US10835492 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 28 Jun, 2023 | US8092828 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 08 Mar, 2023 | US8022279 |
| Correspondence Address Change Critical | 07 Mar, 2023 | US8518437 |
| Correspondence Address Change Critical | 27 Feb, 2023 | US8431806 |
| Correspondence Address Change Critical | 27 Feb, 2023 | US8092828 |
| Email Notification Critical | 03 Jan, 2023 | US10835492 |
| Change in Power of Attorney (May Include Associate POA) Critical | 03 Jan, 2023 | US10028912 |
| Change in Power of Attorney (May Include Associate POA) Critical | 03 Jan, 2023 | US8092828 |
| Email Notification Critical | 03 Jan, 2023 | US10166184 |
Cytarabine; Daunorubicin's Family Patents
